Citius Pharma publishes corporate deck spotlighting LYMPHIR launch, Mino-Lok Phase 3, Halo-Lido program

Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc

CTXR

0.00
  • Citius Pharmaceuticals outlined a commercial ramp for LYMPHIR, launched in Dec 2025 for relapsed or refractory Stage I-III CTCL.
  • Reported USD 5.6 million revenue in fiscal 1H 2026; 83% of target accounts on formulary or in review; about 100% covered lives.
  • Highlighted Mino-Lok Phase 3 completion in 2024; trial met primary and secondary endpoints for catheter salvage in CLABSI.
  • Pointed to recent financings totaling USD 41.5 million in April-May 2026; cash runway projected into November 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.